For Healthcare Professionals Only

Important Safety InformationPrescribing Information
Important Safety InformationPrescribing Information

References

  1. Data on file. Harrow IP, LLC; 2023.
  2. Iheezo. Prescribing information. Harrow IP, LLC; 2022.
  3. Shah HR, Reichel E, Busbee BG. A novel lidocaine hydrochloride ophthalmic gel for topical ocular anesthesia. Local Reg Anesth. 2010;3:57-63.
  4. Rinella Han J, Rinella NT, Chao DL. Anesthesia for intravitreal injection: a systematic review. Clin Ophthalmol. 2020;14:543-550.
  5. Sintetica. Chloroprocaine hydrochloride ophthalmic gel 3%. Pharmaceutical Development. Sintetica; 2002.
  6. Akten. Material safety data sheet. Akorn Pharmaceuticals; 2010.
  7. Costine Ilyas H, Costine R. The Effects of Low Viscosity Preservative-Free Chloroprocaine Ophthalmic Gel 3% versus BAK-Containing Tetracaine 0.5% on the Bactericidal Action of Povidone-Iodine. Clin Ophthalmol. 2024;18:825-831 https://doi.org/10.2147/OPTH.S454496.
  8. IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.
  9. Intravitreal Injections. The Foundation of the American Society of Retina Specialists. Accessed October 30, 2022. https://www.asrs.org/content/documents/fact-sheet-30-intravitreal-injections.pdf.

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

  • IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.
  • IHEEZO should not be injected or intraocularly administered.
  • Patients should not touch the eye for at least 10 to 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.
  • Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.
  • Do not touch the dropper tip to any surface as this may contaminate the gel.
  • IHEEZO is indicated for administration under the direct supervision of a healthcare provider. IHEEZO is not intended for patient self-administration.
  • The most common adverse reactions in studies following IHEEZO administration (incidence greater than or equal to 5%) were mydriasis, conjunctival hyperemia, and eye irritation.
  • You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
  • For additional information about IHEEZO, please see the full Prescribing Information.

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

  • IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.
  • IHEEZO should not be injected or intraocularly administered.
  • Patients should not touch the eye for at least 10 to 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.
  • Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.
  • Do not touch the dropper tip to any surface as this may contaminate the gel.
  • IHEEZO is indicated for administration under the direct supervision of a healthcare provider. IHEEZO is not intended for patient self-administration.
  • The most common adverse reactions in studies following IHEEZO administration (incidence greater than or equal to 5%) were mydriasis, conjunctival hyperemia, and eye irritation.
  • You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
  • For additional information about IHEEZO, please see the full Prescribing Information.